Vertex Pharmaceuticals (MA) Goes From Bad Data to a Bad Promotion
Published: Jun 01, 2012
This is not a good week for the executive team at Vertex Pharmaceuticals. Two days ago, the drugmaker revised previously announced interim results of a Phase II study of a combination cystic fibrosis treatment, taking the wind out of its once hot stock and tarnishing its credibility (see here). Now, the FDA has issued a so-called untitled letter for a promotional push for its Incivek hepatitis C treatment for including misleading material.